Annual CFO
$159.26 M
-$16.64 M-9.46%
31 December 2023
Summary:
BioMarin Pharmaceutical annual cash flow from operations is currently $159.26 million, with the most recent change of -$16.64 million (-9.46%) on 31 December 2023. During the last 3 years, it has risen by +$73.89 million (+86.56%). BMRN annual CFO is now -47.70% below its all-time high of $304.54 million, reached on 31 December 2021.BMRN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$221.48 M
+$102.72 M+86.49%
30 September 2024
Summary:
BioMarin Pharmaceutical quarterly cash flow from operations is currently $221.48 million, with the most recent change of +$102.72 million (+86.49%) on 30 September 2024. Over the past year, it has increased by +$85.83 million (+63.28%). BMRN quarterly CFO is now at all-time high.BMRN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$414.70 M
+$85.83 M+26.10%
30 September 2024
Summary:
BioMarin Pharmaceutical TTM cash flow from operations is currently $414.70 million, with the most recent change of +$85.83 million (+26.10%) on 30 September 2024. Over the past year, it has increased by +$276.13 million (+199.29%). BMRN TTM CFO is now at all-time high.BMRN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.5% | +63.3% | +199.3% |
| 3 y3 years | +86.6% | +128.2% | +48.1% |
| 5 y5 years | +688.1% | +215.8% | +929.2% |
BMRN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -47.7% | +86.6% | at high | +399.6% | at high | +248.4% |
| 5 y | 5 years | -47.7% | +688.1% | at high | +399.6% | at high | +929.2% |
| alltime | all time | -47.7% | +169.9% | at high | +229.2% | at high | +241.3% |
BioMarin Pharmaceutical Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $221.48 M(+86.5%) | $414.70 M(+26.1%) |
| June 2024 | - | $118.76 M(+152.8%) | $328.86 M(+17.4%) |
| Mar 2024 | - | $46.97 M(+70.9%) | $280.16 M(+75.9%) |
| Dec 2023 | $159.26 M(-9.5%) | $27.48 M(-79.7%) | $159.26 M(+14.9%) |
| Sept 2023 | - | $135.65 M(+93.6%) | $138.56 M(-14.1%) |
| June 2023 | - | $70.06 M(-194.8%) | $161.24 M(+9.4%) |
| Mar 2023 | - | -$73.93 M(-1189.5%) | $147.40 M(-16.2%) |
| Dec 2022 | $175.90 M(-42.2%) | $6.79 M(-95.7%) | $175.90 M(-2.4%) |
| Sept 2022 | - | $158.32 M(+181.6%) | $180.30 M(+51.5%) |
| June 2022 | - | $56.23 M(-223.8%) | $119.03 M(-18.2%) |
| Mar 2022 | - | -$45.43 M(-506.4%) | $145.59 M(-52.2%) |
| Dec 2021 | $304.54 M(+256.7%) | $11.18 M(-88.5%) | $304.54 M(+8.8%) |
| Sept 2021 | - | $97.06 M(+17.2%) | $279.97 M(+4.0%) |
| June 2021 | - | $82.78 M(-27.1%) | $269.12 M(+25.7%) |
| Mar 2021 | - | $113.51 M(-948.1%) | $214.07 M(+150.8%) |
| Dec 2020 | $85.36 M(+76.9%) | -$13.38 M(-115.5%) | $85.36 M(-45.3%) |
| Sept 2020 | - | $86.21 M(+210.8%) | $156.09 M(+11.5%) |
| June 2020 | - | $27.74 M(-282.6%) | $140.01 M(+59.2%) |
| Mar 2020 | - | -$15.19 M(-126.5%) | $87.94 M(+82.2%) |
| Dec 2019 | $48.26 M(+138.8%) | $57.34 M(-18.2%) | $48.26 M(+19.8%) |
| Sept 2019 | - | $70.13 M(-388.1%) | $40.29 M(+132.0%) |
| June 2019 | - | -$24.34 M(-55.6%) | $17.37 M(+121.3%) |
| Mar 2019 | - | -$54.87 M(-211.1%) | $7.85 M(-61.2%) |
| Dec 2018 | $20.21 M(-330.8%) | $49.37 M(+4.6%) | $20.21 M(-238.9%) |
| Sept 2018 | - | $47.20 M(-239.4%) | -$14.55 M(-38.0%) |
| June 2018 | - | -$33.86 M(-20.4%) | -$23.46 M(-180.4%) |
| Mar 2018 | - | -$42.51 M(-390.9%) | $29.18 M(-433.2%) |
| Dec 2017 | -$8.76 M(-96.2%) | $14.61 M(-61.8%) | -$8.76 M(-62.9%) |
| Sept 2017 | - | $38.29 M(+103.9%) | -$23.58 M(-67.4%) |
| June 2017 | - | $18.78 M(-123.3%) | -$72.24 M(-47.2%) |
| Mar 2017 | - | -$80.44 M(>+9900.0%) | -$136.83 M(-39.9%) |
| Dec 2016 | -$227.84 M(+3.8%) | -$210.00 K(-98.0%) | -$227.84 M(-22.4%) |
| Sept 2016 | - | -$10.37 M(-77.4%) | -$293.47 M(+2.6%) |
| June 2016 | - | -$45.80 M(-73.3%) | -$285.96 M(+13.0%) |
| Mar 2016 | - | -$171.45 M(+160.4%) | -$253.14 M(+15.3%) |
| Dec 2015 | -$219.50 M(+211.7%) | -$65.85 M(+2210.4%) | -$219.50 M(+23.6%) |
| Sept 2015 | - | -$2.85 M(-78.1%) | -$177.56 M(-3.1%) |
| June 2015 | - | -$12.99 M(-90.6%) | -$183.27 M(+0.8%) |
| Mar 2015 | - | -$137.81 M(+476.4%) | -$181.74 M(+158.1%) |
| Dec 2014 | -$70.42 M(+22.8%) | -$23.91 M(+179.4%) | -$70.42 M(+26.9%) |
| Sept 2014 | - | -$8.56 M(-25.4%) | -$55.51 M(-1.7%) |
| June 2014 | - | -$11.46 M(-56.7%) | -$56.45 M(+9.0%) |
| Mar 2014 | - | -$26.49 M(+194.5%) | -$51.80 M(-9.7%) |
| Dec 2013 | -$57.34 M(-425.6%) | -$9.00 M(-5.2%) | -$57.34 M(+57.7%) |
| Sept 2013 | - | -$9.49 M(+39.2%) | -$36.35 M(+187.5%) |
| June 2013 | - | -$6.82 M(-78.7%) | -$12.65 M(+74.5%) |
| Mar 2013 | - | -$32.03 M(-367.2%) | -$7.25 M(-141.2%) |
| Dec 2012 | $17.61 M(-4.4%) | $11.99 M(-15.7%) | $17.61 M(+244.6%) |
| Sept 2012 | - | $14.21 M(-1101.0%) | $5.11 M(-2202.9%) |
| June 2012 | - | -$1.42 M(-80.2%) | -$243.00 K(-101.6%) |
| Mar 2012 | - | -$7.17 M(+1297.9%) | $14.74 M(-19.9%) |
| Dec 2011 | $18.41 M | -$513.00 K(-105.8%) | $18.41 M(+485.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | $8.86 M(-34.7%) | $3.15 M(-5.9%) |
| June 2011 | - | $13.57 M(-487.7%) | $3.34 M(-72.1%) |
| Mar 2011 | - | -$3.50 M(-77.8%) | $12.00 M(-36.0%) |
| Dec 2010 | $18.75 M(-78.6%) | -$15.78 M(-274.3%) | $18.75 M(-65.3%) |
| Sept 2010 | - | $9.06 M(-59.2%) | $53.99 M(-26.4%) |
| June 2010 | - | $22.22 M(+583.7%) | $73.37 M(+3.4%) |
| Mar 2010 | - | $3.25 M(-83.3%) | $70.96 M(-19.1%) |
| Dec 2009 | $87.73 M(-1056.2%) | $19.47 M(-31.5%) | $87.73 M(+22.6%) |
| Sept 2009 | - | $28.43 M(+43.5%) | $71.58 M(+52.6%) |
| June 2009 | - | $19.81 M(-1.0%) | $46.90 M(+41.8%) |
| Mar 2009 | - | $20.02 M(+504.1%) | $33.06 M(-460.4%) |
| Dec 2008 | -$9.18 M(-73.4%) | $3.31 M(-11.7%) | -$9.18 M(-12.1%) |
| Sept 2008 | - | $3.75 M(-37.2%) | -$10.44 M(-56.3%) |
| June 2008 | - | $5.98 M(-126.9%) | -$23.91 M(-34.6%) |
| Mar 2008 | - | -$22.22 M(-1185.5%) | -$36.57 M(+6.0%) |
| Dec 2007 | -$34.49 M(-33.9%) | $2.05 M(-121.1%) | -$34.49 M(-30.1%) |
| Sept 2007 | - | -$9.72 M(+45.5%) | -$49.35 M(-5.4%) |
| June 2007 | - | -$6.68 M(-66.8%) | -$52.18 M(-1.4%) |
| Mar 2007 | - | -$20.15 M(+57.3%) | -$52.94 M(+1.5%) |
| Dec 2006 | -$52.17 M(-11.8%) | -$12.81 M(+2.1%) | -$52.17 M(-4.3%) |
| Sept 2006 | - | -$12.55 M(+68.7%) | -$54.50 M(-14.9%) |
| June 2006 | - | -$7.44 M(-61.6%) | -$64.04 M(+6.5%) |
| Mar 2006 | - | -$19.38 M(+28.0%) | -$60.12 M(+1.6%) |
| Dec 2005 | -$59.15 M(+15.9%) | -$15.14 M(-31.4%) | -$59.15 M(+14.2%) |
| Sept 2005 | - | -$22.08 M(+526.6%) | -$51.81 M(+19.0%) |
| June 2005 | - | -$3.52 M(-80.9%) | -$43.54 M(-24.1%) |
| Mar 2005 | - | -$18.40 M(+135.9%) | -$57.36 M(+12.4%) |
| Dec 2004 | -$51.05 M(-31.8%) | -$7.80 M(-43.5%) | -$51.05 M(-33.0%) |
| Sept 2004 | - | -$13.81 M(-20.3%) | -$76.23 M(-10.4%) |
| June 2004 | - | -$17.34 M(+43.4%) | -$85.06 M(+13.3%) |
| Mar 2004 | - | -$12.09 M(-63.3%) | -$75.10 M(+0.4%) |
| Dec 2003 | -$74.80 M(+39.6%) | -$32.99 M(+45.7%) | -$74.80 M(-1.6%) |
| Sept 2003 | - | -$22.64 M(+206.9%) | -$76.01 M(+27.7%) |
| June 2003 | - | -$7.38 M(-37.5%) | -$59.52 M(+4.3%) |
| Mar 2003 | - | -$11.80 M(-65.5%) | -$57.06 M(+6.5%) |
| Dec 2002 | -$53.59 M(+31.2%) | -$34.20 M(+456.0%) | -$53.59 M(+25.1%) |
| Sept 2002 | - | -$6.15 M(+25.2%) | -$42.84 M(+0.2%) |
| June 2002 | - | -$4.91 M(-41.1%) | -$42.78 M(+6.9%) |
| Mar 2002 | - | -$8.33 M(-64.5%) | -$40.03 M(-2.0%) |
| Dec 2001 | -$40.85 M(+220.8%) | -$23.45 M(+285.3%) | -$40.85 M(+103.2%) |
| Sept 2001 | - | -$6.09 M(+181.5%) | -$20.11 M(+28.2%) |
| June 2001 | - | -$2.16 M(-76.4%) | -$15.69 M(-2.2%) |
| Mar 2001 | - | -$9.15 M(+238.3%) | -$16.04 M(+26.0%) |
| Dec 2000 | -$12.73 M(-1.6%) | -$2.71 M(+62.6%) | -$12.73 M(-3.3%) |
| Sept 2000 | - | -$1.66 M(-34.0%) | -$13.17 M(-27.7%) |
| June 2000 | - | -$2.52 M(-56.9%) | -$18.20 M(+23.9%) |
| Mar 2000 | - | -$5.84 M(+86.1%) | -$14.69 M(+13.5%) |
| Dec 1999 | -$12.94 M(+59.8%) | -$3.14 M(-53.1%) | -$12.94 M(+32.0%) |
| Sept 1999 | - | -$6.70 M(-773.4%) | -$9.80 M(+216.1%) |
| June 1999 | - | $995.00 K(-124.3%) | -$3.10 M(-24.3%) |
| Mar 1999 | - | -$4.09 M | -$4.09 M |
| Dec 1998 | -$8.10 M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual cash flow from operations?
- What is the all time high annual CFO for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual CFO year-on-year change?
- What is BioMarin Pharmaceutical quarterly cash flow from operations?
- What is the all time high quarterly CFO for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly CFO year-on-year change?
- What is BioMarin Pharmaceutical TTM cash flow from operations?
- What is the all time high TTM CFO for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM CFO year-on-year change?
What is BioMarin Pharmaceutical annual cash flow from operations?
The current annual CFO of BMRN is $159.26 M
What is the all time high annual CFO for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual cash flow from operations is $304.54 M
What is BioMarin Pharmaceutical annual CFO year-on-year change?
Over the past year, BMRN annual cash flow from operations has changed by -$16.64 M (-9.46%)
What is BioMarin Pharmaceutical quarterly cash flow from operations?
The current quarterly CFO of BMRN is $221.48 M
What is the all time high quarterly CFO for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly cash flow from operations is $221.48 M
What is BioMarin Pharmaceutical quarterly CFO year-on-year change?
Over the past year, BMRN quarterly cash flow from operations has changed by +$85.83 M (+63.28%)
What is BioMarin Pharmaceutical TTM cash flow from operations?
The current TTM CFO of BMRN is $414.70 M
What is the all time high TTM CFO for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM cash flow from operations is $414.70 M
What is BioMarin Pharmaceutical TTM CFO year-on-year change?
Over the past year, BMRN TTM cash flow from operations has changed by +$276.13 M (+199.29%)